Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockDoctor101on Nov 28, 2022 12:54pm

149 Views

Post# 35134158

Looking at AGN @ $2.47

I like the tight float of AGN. Seems to be holding around $2.5 but some promising results from their DMT trials could get it moving again. Phase II trials could also start as early as next year on human stroke patients - will be something to look out for.

They recently commenced screening subjects for the Phase I DMT study which will identify the safety, tolerability, and pharmacokinetics of DMT. Preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor, an important part of brain recovery.

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-screens-first-subject-120000046.html

<< Previous

Bullboard Posts

Next >>

Nintendo stock hits new all-time high as excitement builds over Switch successor